4d pharma (4d pharma) Cash-to-Debt : 1.56 (As of Dec. 2021)

View and export this data going back to 2021. Start your Free Trial

What is 4d pharma Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. 4d pharma's cash to debt ratio for the quarter that ended in Dec. 2021 was 1.56.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, 4d pharma could pay off its debt using the cash in hand for the quarter that ended in Dec. 2021.

The historical rank and industry rank for 4d pharma's Cash-to-Debt or its related term are showing as below:

LBPWQ' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.56 Med: 1198.78 Max: No Debt
Current: 1.56

During the past 8 years, 4d pharma's highest Cash to Debt Ratio was No Debt. The lowest was 1.56. And the median was 1198.78.

LBPWQ's Cash-to-Debt is not ranked
in the Biotechnology industry.
Industry Median: 6.485 vs LBPWQ: 1.56

4d pharma Cash-to-Debt Historical Data

The historical data trend for 4d pharma's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

4d pharma Cash-to-Debt Chart

4d pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Cash-to-Debt

Get a 7-Day Free Trial

1,396.27

1,006.03

3.82

8.29

1.56

4d pharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21
Cash-to-Debt	Get a 7-Day Free Trial											3.82	9.12	8.29	20.53	1.56

Competitive Comparison of 4d pharma's Cash-to-Debt

For the Biotechnology subindustry, 4d pharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

4d pharma's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 4d pharma's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where 4d pharma's Cash-to-Debt falls into.

4d pharma Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

4d pharma's Cash to Debt Ratio for the fiscal year that ended in Dec. 2021 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	20.608	/	(0.106	+	13.098)
	=	1.56

4d pharma's Cash to Debt Ratio for the quarter that ended in Dec. 2021 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	20.608	/	(0.106	+	13.098)
	=	1.56

4d pharma (OTCPK:LBPWQ) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

4d pharma Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of 4d pharma's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

4d pharma (4d pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4d pharma PLC (OTCPK:LBPWQ) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

9 Bond Court, Fifth Floor, Leeds, GBR, LS1 2JZ

Website

https://www.4dpharmaplc.com

4d pharma PLC and its subsidiaries are in the business of research and development and production of live biotherapeutic products. The company develops biotherapeutic products for diseases such as cancer, asthma, autism, and autoimmune conditions such as arthritis and multiple sclerosis. Its developing science includes Live biotherapeutics, Microbiome, MicroRx, MicroDx, and others.